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ABSTRACT
Asthma is a chronic inflammatory disease of the airways 
characterized by airway hyperresponsiveness and airflow 
obstruction. Chronic airway inflammation can lead to an 
increase in thickness of airway smooth muscle which causes 
airflow constriction and breathing difficulty. Clinical trials have 
demonstrated significant improvements on asthma patients who 
received bronchial thermoplasty (BT).
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Bronchial thermoplasty treatment
Bronchial thermoplasty (BT) is a new treatment modality 
in severe asthma. It is a bronchoscopic procedure in which 
the large sub-segmental airways are heated to 65°C by an 
electrode with radiofrequency energy which ablates and 
reduces the bronchial smooth muscle mass. It is performed 
with fiberoptic bronchoscopy in 3 separate procedures in 
which all accessible airways located beyond the main stem 
bronchi (average of 3-10 mm in diameter), one for the each 
lower lobe of the lung and another for both upper lobes. 
The delivery of energy during bronchial thermoplasty uses 
continuous feedback to control the degree and time of tissue 
heating to decrease airway smooth muscle mass without 
airway perforation or stenosis. Most patients with difficult-
to-treat asthma require 3-4 medications and long-term oral 
corticosteroids or frequent use [1]. Alternative therapies 
have offered the advantage of preventing the major side 
effect of steroids [2].
Selection of treatment candidates is an important step. 
Patients between 18-65 years of age, non-smoker for at least 
the preceding year and patients who have severe asthma 
not well controlled by inhaled corticosteroids and long-
acting bronchodilators can be appropriate. The use of this 
technology to treat asthma was used first in animals and 
then it was later performed in patients with asthma [3,4]. In 
vivo and in vitro studies have shown that anti-inflammatory 
effects of glucocorticoids were decreased in patients with 
severe asthma [5]. Therefore, new treatment modalities were 
experienced in this field and GINA guideline recommends 
BT to be considered step 5 therapy in patients with 
uncontrolled severe asthma ( evidence level A).
The Asthma Intervention Research trial was the first 
randomized controlled trial of BT and conventional therapy. 
BT group had 50% fewer mild exacerbations in the following 
12 months. BT group had more adverse respiratory events 
and hospitalizations after the procedure but after 6 weeks 
there was no difference between the two groups. After one 
year, there was more improvements in Asthma Control 
Questionnaire and Asthma Quality of Life Questionnaire 
scores. The most common adverse events were dyspnea, 
wheezing, cough and chest discomfort [7,8].
The Asthma Intervention Research 2 trial which is a 
randomized clinical trial of BT in patients with severe 
asthma, showed a reduction in severe exacerbations and 
reduction in emergency visits due to respiratory symptoms 
[9-11].
There are many contraindications for BT which include 
an age younger than 18 years, patients who have pacemaker, 
other implantable devices, an allergy to a medication used 
in bronchoscopy like atropine, lidocaine. This procedure 
must be postponed if a patient have an asthma exacerbation, 
respiratory infections or coagulopathy [12]. 
In this procedure, severity of lung function should not 
be used as indication. BT can be performed in patients who 
have important symptoms that are uncontrolled despite 
all medications. It is not clear which asthma phenotypes 
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should be chosen for BT. But there is no clear information 
to consider one option over the others. BT is effective in 
central airway obstruction as seen in patients with asthma. 
Location is very important in this procedure.
Conclusion 
BT becomes more widely accepted as a treatment option 
for patients with uncontrolled asthma. Clinical studies 
indicate an improvement in quality of life. More research is 
needed to determine which asthma phenotypes should BT 
be preferred. 
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